Literature DB >> 10989189

Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors.

Y Zermati1, S Fichelson, F Valensi, J M Freyssinier, P Rouyer-Fessard, E Cramer, J Guichard, B Varet, O Hermine.   

Abstract

Erythropoiesis is positively regulated by stem cell factor, interleukin 3, and erythropoietin, which synergize to allow the production of hemoglobinized red blood cells from erythroid progenitors. In contrast, interferon gamma, tumor necrosis factor alpha, and transforming growth factor B(1), (TGF-beta(1)) are powerful inhibitors of erythropoiesis. Interferon gamma and alpha act principally by inducing apoptosis. The aim of this study was to elucidate the mechanisms by which TGF-beta(1) inhibits erythropoiesis. We used an in vitro serum-free system of human red blood cell production. From a virtually pure population of CD36(+) erythroid progenitors, stem cell factor, interleukin 3, and erythropoietin allowed massive proliferation (x300) and promoted terminal red blood cell differentiation. We show here that TGF-beta(1) (2 ng/mL) inhibited the growth of CD36(+) cells by 15-fold. TGF-beta(1) markedly accelerated and increased erythroid differentiation as assessed by hemoglobin and glycophorin expression. Furthermore, May-Grünwald-Giemsa staining and ultrastructural analysis revealed that TGF-beta(1) induced full differentiation toward normal enucleated red cells even in the absence of macrophages. This acceleration of erythroid differentiation did not modify the pattern of hemoglobin chains expression from adult or fetal erythroid progenitors. Analysis of apoptosis, cell cycle and Ki-67 expression showed that TGF-beta(1) inhibited cell proliferation by decreasing the cycle of immature erythroid cells and accelerating maturation toward orthochromatic normoblasts that are not in cycle. We showed that TGF-beta(1) is a paradoxical inhibitor of erythropoiesis that acts by blocking proliferation and accelerating differentiation of erythroid progenitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10989189     DOI: 10.1016/s0301-472x(00)00488-4

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  46 in total

Review 1.  Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Leukemia       Date:  2019-04-08       Impact factor: 11.528

2.  HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia.

Authors:  Jean-Benoît Arlet; Jean-Antoine Ribeil; Flavia Guillem; Olivier Negre; Adonis Hazoume; Guillaume Marcion; Yves Beuzard; Michaël Dussiot; Ivan Cruz Moura; Samuel Demarest; Isaure Chauvot de Beauchêne; Zakia Belaid-Choucair; Margaux Sevin; Thiago Trovati Maciel; Christian Auclair; Philippe Leboulch; Stany Chretien; Luba Tchertanov; Véronique Baudin-Creuza; Renaud Seigneuric; Michaela Fontenay; Carmen Garrido; Olivier Hermine; Geneviève Courtois
Journal:  Nature       Date:  2014-08-24       Impact factor: 49.962

3.  Expansion of CD34+ cells on telomerized human stromal cells without losing erythroid-differentiation potential in a serum-free condition.

Authors:  Masayoshi Kobune; Yutaka Kawano; Junji Kato; Yoshinori Ito; Hiroki Chiba; Kiminori Nakamura; Akihito Fujimi; Takuya Matsunaga; Hirofumi Hamada; Yoshiro Niitsu
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

Review 4.  Erythroblastic islands: niches for erythropoiesis.

Authors:  Joel Anne Chasis; Narla Mohandas
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

5.  An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.

Authors:  Michael Dussiot; Thiago T Maciel; Aurélie Fricot; Céline Chartier; Olivier Negre; Joel Veiga; Damien Grapton; Etienne Paubelle; Emmanuel Payen; Yves Beuzard; Philippe Leboulch; Jean-Antoine Ribeil; Jean-Benoit Arlet; Francine Coté; Geneviève Courtois; Yelena Z Ginzburg; Thomas O Daniel; Rajesh Chopra; Victoria Sung; Olivier Hermine; Ivan C Moura
Journal:  Nat Med       Date:  2014-03-23       Impact factor: 53.440

6.  Prospective isolation of human erythroid lineage-committed progenitors.

Authors:  Yasuo Mori; James Y Chen; John V Pluvinage; Jun Seita; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-20       Impact factor: 11.205

7.  Aberrant erythropoiesis fuels tumor growth.

Authors:  Kyohei Nakamura; Mark J Smyth
Journal:  Cell Res       Date:  2018-06       Impact factor: 25.617

8.  Unexpected macrophage-independent dyserythropoiesis in Gaucher disease.

Authors:  Nelly Reihani; Jean-Benoit Arlet; Michael Dussiot; Thierry Billette de Villemeur; Nadia Belmatoug; Christian Rose; Yves Colin-Aronovicz; Olivier Hermine; Caroline Le Van Kim; Melanie Franco
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

9.  MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathway.

Authors:  Chutima Kumkhaek; Wulin Aerbajinai; Wenli Liu; Jianqiong Zhu; Naoya Uchida; Roger Kurlander; Matthew M Hsieh; John F Tisdale; Griffin P Rodgers
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

10.  Fibrillin-1 microfibrils influence adult bone marrow hematopoiesis.

Authors:  Silvia Smaldone; Carolina L Bigarella; Maria Del Solar; Saghi Ghaffari; Francesco Ramirez
Journal:  Matrix Biol       Date:  2015-11-29       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.